Idhifa (Enasidenib Mesylate) Patent Expiration, LOE Window & CMS Spending

Idhifa (Enasidenib Mesylate) by Bristol Myers Squibb: FDA Orange Book core substance LOE 2034-09-16, 0 AB generics, $196.2M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBristol Myers Squibb
FDA Application & PathwayN209606 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2034-09-16
Last Listed Patent or Exclusivity Date2034-09-16
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$196.2M
2024 Medicare Part D Spend$184.7M
2024 Medicaid Spend$11.5M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 22.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.